Nanoparticles can overcome drug resistance in breast cancer cells
In their experiments, the researchers used breast cancer cells that responded poorly to drugs owing to their high concentrations of the enzyme microsomal glutathione S-transferase-1 (MGST-1). Abnormally high levels of MGST-1 have been associated with poor responses to several cancer drugs. The team treated the resistant breast cancer cells with nanoparticles filled with doxorubicin, a chemotherapeutic used clinically to treat bladder, lung, ovarian and breast cancer, amongst others.
“Our experiments on cultivated cells showed that the particles themselves are harmless,” says research team member Dr Andreas Nyström, Associate Professor at the Institute of Environmental Medicine, Karolinska Institutet. “We made it possible for the nanoparticles carrying the drug to kill resistant cancer cells by controlling where in the cancer cell they delivered their payload. This improved the efficacy of the drug even at a much lower dose, which is important for limiting the adverse reactions to therapy.”
Nanoparticles can also be used to control where the drug is delivered in the body, and the team is now planning to equip them with targeting groups such as peptides or antibodies, that direct them to specific tumour cells to increase the uptake of the particles and their drug content by the tumour while sparing healthy cells.
Most read news
Other news from the department science
These products might interest you
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.